T-Knife has emerged from stealth with $77.6m in series A funding to advance four potential cancer treatments into the clinic and open a US office.
T-Knife, a Germany-based T-cell receptor therapeutics spinout of Max Delbrück Center for Molecular Medicine (MDC), has raised €66m ($77.6m) in a series A round co-led by Versant Ventures and RA Capital Management.
Boehringer Ingelheim Venture Fund (BIVF), the corporate venturing unit for pharmaceutical firm Boehringer Ingelheim, and Andera Partners also took part in the round, which remains subject to regulatory clearance.
Founded in 2018, T-Knife is working on cancer drugs based on T-cell receptors (TCRs) made using mice…
